Published on GHDx (https://ghdx.healthdata.org)

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

General Info

Geography 
United States of America (USA)
Time period covered 
January, 2008 - December, 2013
Data type
Scientific literature
Keywords 
Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors 
Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV
Journal 
Leukemia
Pages 
995-8
Publication year 
2016
Suggested citation 
Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. Leukemia. 2016; 30(4): 995-8.
Source URL:https://ghdx.healthdata.org/record/treatment-outcomes-health-care-resource-utilization-and-costs-bortezomib-and-dexamethasone#comment-0